

Explore by topic
2020–2024 (relevant background) — Siemens Healthineers' Varian acquisition closes (impact felt into 2024)
Siemens Healthineers completed acquisition of Varian (initial agreement announced 2020; closing completed Feb 26, 2024) — this extended Healthineers' oncology position. Siemens, as majority holder of Healthineers, welcomed the strategic rationale and monitored implications for group portfolio.
The Varian deal strengthened Healthineers' growth profile. For Siemens shareholders the deal increased the complexity and size of the consolidated Healthineers exposure, which later fed into discussions about deconsolidation and portfolio simplification.
Varian acquisition price originally USD 177.50 per share (agreement announced Aug 2020); completion announced Feb 26, 2024 by Siemens Healthineers [1][2][8].
2021 — Siemens executes strategy through portfolio focus and management messaging (strategic context)
Through 2021 Siemens continued executing Vision 2020+ and reorganisations that emphasized digitalization and software-led industrial offerings. Investor communications framed Siemens' transformation toward higher-margin digital/automation offerings.
Investor perception moved from pure cyclical industrial exposure toward a long-term compounder thesis anchored in automation, software, mobility and infrastructure digitalization — although cyclical risks remained a frequent analyst caveat [2][6].
2021–2024 (program period) — Share buyback program started Nov 2021 and large buyback activity through early 2024
Siemens authorized and executed a share repurchase program announced November 2021 (up to €3 billion) which was later executed and completed early in January 2024.
The buyback program reinforced shareholder-return credibility after previous restructuring and portfolio moves. Investors saw buybacks as management's tool to improve EPS and return capital amid structural transformation.
Share buyback announced 15 Nov 2021 (up to €3 billion) and completed early on 25 Jan 2024 with total repurchases of €3.0 billion [6].
2024 — Siemens reiterates Vision 2020+ legacy and reports FY2024 results
Siemens published fiscal 2024 results and annual report metrics. Management continued communicating the "ONE Tech Company" strategy that combines digital and hardware strengths and emphasised industrial AI and sustainability. The FY2024 report included financials and continuation of buyback/dividend policy disclosures.
Investors increasingly viewed Siemens as a diversified industrial-tech compounder with strong cash generation, moving the narrative from cyclical industrial to higher-quality technology-led industrials with recurring software/service revenue potential.
Fiscal 2024 revenue €75.9 billion; net income €9.0 billion; employees ~312,000 as of Sept 30, 2024 [web:call_OLOkTI93AtLs9lLXsViy3ZVk][6][3].
2024 Q4 / FY2024 — Completion of prior €3bn buyback and announcement of new €6bn program
Siemens completed the share buyback that started November 15, 2021 early (total €3.0 billion purchased, completed 25 Jan 2024) and announced a new buyback program on 16 Nov 2023 of up to €6 billion for up to five years (commenced 12 Feb 2024).
Share repurchases became an explicit pillar of shareholder returns. Investors viewed buybacks plus rising dividends as management overweighting capital returns to boost per-share metrics while executing strategic simplification. The early completion of the €3bn program was read as opportunistic share-price management and confidence in cash generation.
Completed buyback volume €3.0 billion (program started 15 Nov 2021, completed 25 Jan 2024) and new program up to €6.0 billion announced 16 Nov 2023 and started 12 Feb 2024 (limit: purchases of no more than 80 million shares) [6][4].
2025-11-12 — Siemens announces plan to deconsolidate Siemens Healthineers (spin-off of ~30% to Siemens shareholders)
Siemens announced intention to deconsolidate its remaining stake in Siemens Healthineers by transferring about 30% of Siemens Healthineers shares to Siemens AG shareholders by way of a direct spin-off (reducing Siemens' stake from circa 67% to a significant minority over time). The company said further details would follow and the transaction was subject to approvals and regulatory clarifications.
Market and investor narrative shifted toward portfolio simplification and capital-allocation optionality. Siemens positioned itself as a more focused "ONE Tech Company," arguing the step would increase transparency, reduce complexity and unlock shareholder value while retaining a minority stake in Healthineers. Analysts framed the move as a strategic simplification that could accelerate cash returns and sharpen Siemens' industrial/technology growth story.
Siemens Group revenue €75.9 billion (fiscal 2024) and net income €9.0 billion (fiscal 2024); Siemens' stake in Siemens Healthineers circa 67% at announcement; planned transfer: 30% of Healthineers shares to Siemens shareholders [web:call_OLOkTI93AtLs9lLXsViy3ZVk].
2025-11-13 — Siemens reports record FY2025 net income; dividend increase proposed (company release Nov 2025)
Siemens reported record net income for fiscal 2025 and the Supervisory and Managing Boards proposed increasing the dividend (proposed dividend for FY2025 €5.35 per share). Management reiterated commitment to progressive dividend policy and continued share buybacks.
Investor perception reinforced a shareholder-return focus (dividends + buybacks) alongside strategic portfolio moves (Healthineers deconsolidation). The company's message that simplification and capital returns would coexist supported a value-creation storyline rather than pure break-up rhetoric.
Net income €10.4 billion for fiscal 2025 (up 16% vs fiscal 2024 €9.0 billion); proposed dividend €5.35 per share for fiscal 2025 [14].
Siemens AG operates as a diversified industrial-technology conglomerate across electrification, automation, digital industries, mobility and energy. Its primary competitors are large, diversified industrial and energy-equipment groups including GE Vernova, ABB, Schneider Electric, Hitachi, Mitsubishi Electric, and Alstom. These competitors overlap substantially in power generation, grid equipment, industrial automation and transportation. Competition and execution risk have intensified due to rapid electrification, renewable energy deployment, and digitalization. The company faces material risks from project execution and supply-chain disruptions, cyclical exposure in energy and industrial capital expenditure, regulatory and political uncertainty in global infrastructure markets, and competitive pressure from specialized players and low-cost manufacturers.
Siemens AG is a diversified industrial-technology conglomerate operating across electrification, automation, digitalization, mobility, and healthcare. The competitive landscape fragments across these segments, with large specialized peers dominating electrification and energy, industrial automation, rail and mobility, and healthcare. The company faces material exposure to cyclical industrial demand and capital spending patterns. Supply-chain and component shortages remain structural risks. Regulatory and geopolitical constraints—including trade controls, local content requirements, and infrastructure procurement rules—create friction across markets. Competition intensifies from both global incumbents and Chinese suppliers who combine aggressive pricing with vertical integration advantages, a combination that pressures margins in price-sensitive segments.
| Company | Ticker |
|---|---|
| General Electric Company | GE.NYSE |
| ABB Ltd | ABBN.SIX |
| Schneider Electric SE | SU.PA |
| Honeywell International Inc. | HON.NYSE |
| Rockwell Automation, Inc. | ROK.NYSE |
| Alstom SA | ALO.PA |
Receive hand-picked stock recommendations with detailed analyses every week
Start Free Trial| Period | Siemens Aktiengesellschaft | vs DAX | vs S&P 500 (SPY) |
|---|---|---|---|
| 1M | +3.18% | +6.51% | +1.77% |
| 3M | +1.90% | +1.81% | -2.00% |
| 6M | +21.60% | +15.98% | +6.36% |
| 1Y | +17.59% | +14.49% | -0.10% |
| 3Y | +122.71% | +57.63% | +34.63% |
| 5Y | +130.61% | +65.27% | +40.37% |
Receive hand-picked stock recommendations with detailed analyses every week
Start Free TrialHow the company’s key valuation ratios (P/E, P/S, P/B and P/CF) have evolved over time compared to today.
| Period | P/E Ratio | P/S Ratio | P/B Ratio | P/CF Ratio |
|---|---|---|---|---|
| Current | 27.4 | 2.7 | 3.2 | 17.3 |
| 1Y ago | 20.0 | 2.4 | 3.2 | 15.2 |
| 3Y ago | 13.6 | 1.4 | 2.3 | 8.8 |
| 5Y ago | 20.8 | 1.8 | 2.5 | 11.1 |
Long-term record of paid dividends (amount per share and dividend yield at the time of payment).
| Year | Dividend | Yield at payment | Avg. yield |
|---|---|---|---|
| 2026 | 5.35 EUR | 2.08% | 3.32% |
| 2025 | 5.20 EUR | 2.29% | |
| 2024 | 4.70 EUR | 2.77% | |
| 2023 | 4.25 EUR | 2.84% | |
| 2022 | 4.00 EUR | 2.76% | |
| 2021 | 3.50 EUR | 2.57% | |
| 2020 | 3.90 EUR | 3.80% | |
| 2019 | 3.80 EUR | 4.22% | |
| 2018 | 3.70 EUR | 3.36% | |
| 2017 | 3.60 EUR | 3.25% | |
| 2016 | 3.50 EUR | 4.29% | |
| 2015 | 3.30 EUR | 3.67% | |
| 2014 | 3.00 EUR | 3.36% | |
| 2013 | 3.00 EUR | 4.10% | |
| 2012 | 3.00 EUR | 4.44% |
Historical earnings performance shows how consistently the company meets or exceeds analyst expectations. Forward estimates provide insight into expected profitability and growth trajectory.
Selected income statement, balance sheet and cash flow figures. Annual and quarterly, based on reported IFRS/GAAP financials.
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | 78.91B | 75.93B | 74.88B | 71.98B | 62.27B |
| Operating income (EBIT) | 9.09B | 9.56B | 9.45B | 7.40B | 6.69B |
| Net income | 9.62B | 8.30B | 7.95B | 3.72B | 5.26B |
| Free cash flow | 9.08B | 9.58B | 10.09B | 8.16B | 8.27B |
| Total assets | 166.20B | 147.81B | 145.07B | 151.50B | 139.61B |
| Equity | 62.24B | 51.26B | 47.79B | 48.90B | 44.37B |
| Net debt | 41.52B | 38.76B | 36.51B | 40.17B | 39.16B |